ESPR logo

ESPERION THERAPEUTICS INC

ESPRNASDAQ
🏆 #2678 by market capEarnings Nov 4US Equity
$3.19▲ $0.01 (+0.16%)
Latest quote
🔔
Track ESPR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.2%
7d—
14d—
30d—
ytd▼ 13.9%
1y▲ 11.5%
🏦Market Cap
$663M
Small Cap
📈Revenue Growth (YoY)
21.3%
Healthy
📊Gross Margin
65.0%
High
💵FCF Margin
-4.3%
Thin
⚖️P/S Ratio
1.6x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
$3.18 – $3.19
52-Week Range
$1.13 – $4.18
Volume (shares)
1,677,243
Avg Volume (shares)
—
Shares Outstanding
207.9M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$403M
Last Q Revenue
$80M
P/E Ratio
-131.4
P/S Ratio
1.6x
EPS (TTM)
$-0.03
Dividend Yield
0.00%
Dilution (1yr)
+45.5%
ESPR logo

ESPERION THERAPEUTICS INC

ESPR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$403M▲ +21.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.9%▼ −14.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$60M▲ +10.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −45.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
284.6M▲ +45.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$380M▼ −$227M YoY
StockOtter · stockotter.space

About ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100

Analyst Ratings

ⓘ
Consensus
Hold
11 analysts
Strong Buy0
Buy0
Hold8
Sell1
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.